{
    "Question": "Sana Health CES 2024 product highlight and specification",
    "Summary": "Sana Health\n\nProduct 1: SC255\n\n - HIP-modified, BCMA-targeted allogeneic CAR T therapy\n - Expected IND filing in 2024 for multiple myeloma treatment\n - BCMA validated as a target for autologous CAR T therapy in relapsed/refractory multiple myeloma"
}